I have just been diagnosed with acromegaly

Living with Acromegaly

Now that you've been diagnosed, you can focus on living with, understanding, and treating acromegaly.

The good news is that acromegaly treatment is well understood by the medical community.

You might already know something about living with acromegaly from your personal experience. But you probably have questions about what causes it, the symptoms of acromegaly, what treatments are available, and how living with acromegaly may affect your life.

A simple, effective way to treat acromegaly:
Somatuline^® Depot (lanreotide) Injection

Somatuline^®Depot (lanreotide) Injection is a medical treatment that's FDA-approved as an effective, safe, and generally well-tolerated medication for treating acromegaly.

Unlike other treatments, Somatuline^®Depot (lanreotide) Injection comes in a single, ready-to-use, prefilled syringe that is injected in a simple, easy procedure.

Learn more about what causes acromegaly

Read about the causes of this uncomfortable condition.

What are my treatment options?

If you are living with acromegaly, your treatment options may include surgery, medication, and radiation.

Could Somatuline^®Depot (lanreotide) Injection help you?

Last year Somatuline^®Depot (lanreotide) Injection helped 6000 people who are living with acromegaly, including three functional, but typical patients named Dave, Mark, and Karen.
See if you're like Dave, or Mark, or Karen.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

View our injection video